Literature DB >> 6151890

Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

P Lund-Johansen.   

Abstract

The cardinal haemodynamic disturbance in established hypertension is an increased total peripheral resistance and a subnormal blood flow, particularly during exercise. The spontaneously occurring changes in central haemodynamics have been followed in young males with essential hypertension over a 17-year period: a gradual increase in total peripheral resistance and blood pressure, and a gradual fall in cardiac output and stroke volume, have been demonstrated. Labetalol is a unique antihypertensive agent which induces both alpha- and beta-blockade. Numerous studies have shown that when labetalol is given intravenously to patients with mild to moderate essential hypertension, blood pressure falls within a few minutes-partly due to reduction in cardiac output and heart rate and partly due to reduction in total peripheral resistance. In most series the average reduction in blood pressure was 17 to 22%, the reduction in total peripheral resistance 11 to 14%, and the reduction in cardiac output 2 to 10%. Thus, the reduction in cardiac output with labetalol is less than that seen after single-dose injection of beta-blockers without intrinsic sympathomimetic activity. After intravenous injection, the blood pressure-lowering effect is most marked in the upright position and during muscular exercise when cardiac output is usually significantly reduced. Labetalol reduces blood pressure in severe hypertension. Intravenous doses of 0.2 to 0.8 mg/kg bodyweight reduce blood pressure by approximately 20%. This hypotensive effect is partly due to a reduction in total peripheral resistance and partly due to a fall in cardiac index. When the reduction in blood pressure is gradual and moderate (less than 20%), it is mainly produced by a reduction in total peripheral resistance. During long term use labetalol induces haemodynamic changes rather similar to those seen after bolus injection. However, during prolonged use there is a tendency to normalisation in cardiac output and stroke volume; the sustained decrease in blood pressure is mainly due to a reduction in total peripheral resistance. In a recent 6-year follow-up study where 15 patients were studied before treatment and after 1 and 6 years on long term labetalol treatment, a tendency to normalisation of central haemodynamics was found. Over the years total peripheral resistance was gradually reduced by 15 to 20% at rest as well as during exercise. Stroke volume gradually increased and after 6 years of treatment was approximately 10% higher than the pretreatment value. This compensated for the reduced heart rate and no significant reduction in cardiac output was seen either during exercise or at rest.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151890     DOI: 10.2165/00003495-198400282-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

1.  Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.

Authors:  G Koch
Journal:  Br Heart J       Date:  1979-02

2.  The place of alpha-adrenoceptor and beta-adrenoceptor blockade in the treatment of hypertension.

Authors:  F Gross
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

3.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

4.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.

Authors:  T L Svendsen; S Rasmussen; O J Hartling; P E Nielsen; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

6.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

7.  Systemic, pulmonary, and coronary hemodynamic effects of labetalol in hypertensive subjects.

Authors:  J Mehta; R L Feldman; J D Marx; G A Kelly
Journal:  Am J Med       Date:  1983-10-17       Impact factor: 4.965

8.  Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Am J Med       Date:  1983-10-17       Impact factor: 4.965

9.  Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise.

Authors:  P Lund-Johansen; P Omvik
Journal:  J Hypertens       Date:  1983-08       Impact factor: 4.844

10.  Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise.

Authors:  P Lund-Johansen; P Omvik
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

View more
  22 in total

1.  Long-term hemodynamic effects of antihypertensive treatment.

Authors:  P Lund-Johansen; P Omvik; J E Nordrehaug
Journal:  Clin Investig       Date:  1992

Review 2.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  The influence of labetalol on arterial blood gas data, pulmonary haemodynamics and pulmonary shunting.

Authors:  S G De Hert; L G Heytens; R G De Jongh; M P Vercauteren; E A Boeckx; H F Adriaensen
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

4.  PF9404C, a new slow NO donor with beta receptor blocking properties.

Authors:  M Villarroya; C J Herrero; A Ruíz-Nuño; R de Pascual; M del Valle; P Michelena; M Grau; E Carrasco; M G López; A G García
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 5.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

Review 7.  Control of blood pressure in hypertensive neurological emergencies.

Authors:  Lisa Manning; Thompson G Robinson; Craig S Anderson
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 8.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992

Review 9.  Clinical experience with dual-acting drugs in hypertension.

Authors:  K H Rahn
Journal:  Clin Investig       Date:  1992

Review 10.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.